17.07.2019

In July, pharmaceutical company NPO Petrovax Pharm was issued a permit for commissioning the second manufacturing facility in Podolsk, Moscow Region.

The new facility operates two production lines for APIs, solid, soft, and liquid finished dosage forms. The investment in construction exceeded 1B RUB, of which 300M RUB were provided by the Industrial Development Fund as a beneficial loan. The 2,800-square-meter facility was built to the applicable international and Russian GMP requirements and fitted with state-of-the-art equipment providing for maximum process automation while maintaining a high product quality. The implementation of this project will make it possible to increase production of APIs (2,5x), tablets (7x), and suppositories (4x) as soon as in 2020. The new facility is scheduled to be commissioned through the end of 2019.

An extension of manufacturing capacity means additional opportunities for boosting supplies for the Russian market as well as for expanding international localization and manufacturing projects
Stanislav Korsun, Director of Manufacturing and Quality at NPO Petrovax Pharm.

Petrovax Pharm’s state-of-the-art pharmaceutical production complex is one of the most advanced hi-tech biopharma facilities in Russia. In 2018, the complex marked a 10-year anniversary of operations. Its capacity provides for an annual production of 160M doses of pharmaceutical products ranging from API synthesis to a variety of finished dosage forms such as pre-filled syringes, ampoules, vials, tablets, and suppositories.

In partnership with the leading world pharma players such as Pfizer, Abbott, and Boehringer Ingelheim, the facility implements international technology transfer projects for full-cycle immunobiological production. The company exports its pharmaceutical products to the Eurasian Economic Union, Middle East (Iran), and EU (Slovakia) and plans entering the markets of the South America and Southeast Asia.


Proizvodstvennyj_kompleks.jpg



Back to the list